BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Nov. 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.
"ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment. During the third quarter, we strengthened our leadership with the appointment of Professor Peter J. Pitts as Executive Chairman and broadened our engagement with regulators, potential commercial partners, and investors. Professor Pitts has joined the Company in an active executive capacity and is helping lead the regulatory, operational, partnership, and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this important next phase, and we remain resolute in our commitment to advancing what we believe will be a valuable new therapeutic option for the ALS community."
Recent Highlights
Clinical, Scientific, and Regulatory Progress
- Advancing Phase 3b ENDURANCE Readiness & Constructive Regulatory Backdrop. BrainStorm continues to execute on operational, clinical, and manufacturing activities to support the initiation of the Phase 3b ENDURANCE study of NurOwn® (MSC-NTF cells) in earlier-stage ALS patients under its FDA-agreed Special Protocol Assessment (SPA). The Company also notes the FDA's October 2026 launch of its Rare Disease Framework Initiative, aimed at establishing a more holistic, fit-for-purpose regulatory framework for rare diseases with severe unmet medical needs.
- Peer-Reviewed Publication on NurOwn®-Derived Extracellular Vesicles (ExMN). BrainStorm's R&D team published "Beneficial effects of small extracellular vesicles derived from MSC-NTF (NurOwn®) cells on lung inflammation and fibrosis" in Stem Cell Research & Therapy, a Q1-ranked journal (DOI: 10.1186/s13287-026-05303-y). The study demonstrated reduced lung inflammation and fibrosis, improved oxygenation, and protection against subsequent lung injury following inhaled pretreatment in preclinical models, supporting the therapeutic and preventive potential of NurOwn®-Derived Extracellular Vesicles (ExMN).
Corporate and Leadership
- Appointed Professor Peter J. Pitts as Executive Chairman. On July 28, 2026, BrainStorm announced the appointment of Professor Peter J. Pitts, a former FDA Associate Commissioner and co-founder of the Center for Medicine in the Public Interest, as Executive Chairman and Chief Strategic Regulatory and Policy Officer. Professor Pitts, who joined the Board in May 2026, leads the Company's daily operations, partnerships, investor engagement, and regulatory strategy, focused primarily on advancing the Phase 3b ENDURANCE trial. Professor Jacob Frenkel, a member of BrainStorm's leadership team since 2007 and Board Chairman since 2020, transitioned to Senior Advisor.
Industry and Investor Engagement
- Participated in DUPHAT 2026 in Dubai. In August 2026, CEO Chaim Lebovits and Executive Chairman Professor Peter J. Pitts participated in the 31st Dubai International Pharmaceuticals & Technologies Conference and Exhibition (DUPHAT) at the Dubai World Trade Centre. Professor Pitts delivered keynote addresses and moderated panel sessions on regulatory science harmonization and translational collaboration, while BrainStorm's leadership met with regional health regulators, commercial distribution partners, and international investment groups regarding the strategic positioning of NurOwn® and the planned Phase 3b ENDURANCE trial.
Financial Results for the Third Quarter Ended September 30, 2026
- Cash, cash equivalents, and restricted cash were approximately $0.35 million as of September 30, 2026, compared to approximately $0.24 million as of September 30, 2025.
- Research and development expenditures, net, for the third quarter of 2026 were approximately $0.5 million, compared to approximately $0.9 million for the third quarter of 2025.
- General and administrative expenses for the third quarter of 2026 were approximately $1.09 million, compared to approximately $1.15 million for the third quarter of 2025.
- Net loss for the third quarter of 2026 was approximately $1.7 million, compared to a net loss of approximately $2.1 million for the third quarter of 2025.
- Net loss per share for the third quarters of 2026 and 2025 was $(0.14) and $(0.19), respectively.
U.S. dollars in thousands | ||||||
(Except share and per share amounts) | ||||||
September 30, | December 31, | |||||
2026 | 2025 | |||||
Unaudited | Audited | |||||
U.S. $ in thousands | ||||||
ASSETS | ||||||
Current Assets: | ||||||
Cash and cash equivalents | $ | 163 | $ | 29 | ||
Other accounts receivable | 189 | 86 | ||||
Prepaid expenses and other current assets | 101 | 192 | ||||
Total current assets | $ | 453 | $ | 307 | ||
Long-Term Assets: | ||||||
Prepaid expenses and other long-term assets | $ | 26 | $ | 25 | ||
Restricted Cash | 185 | 247 | ||||
Right of use asset | 53 | 208 | ||||
Property and equipment, net | 123 | 235 | ||||
Total Long-Term Assets | $ | 387 | $ | 715 | ||
Total assets | $ | 840 | $ | 1,022 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||
Current Liabilities: | ||||||
Accounts payable | $ | 7,473 | $ | 7,067 | ||
Accrued expenses | 464 | 396 | ||||
Short-term loans | 1,875 | 967 | ||||
Operating lease liability | 56 | 208 | ||||
Employees related liability | 3,304 | 2,369 | ||||
Total current liabilities | $ | 13,172 | $ | 11,007 | ||
Total liabilities | $ | 13,172 | $ | 11,007 | ||
Stockholders' Deficit: | ||||||
Stock capital: | 16 | 16 | ||||
Common stock $0.00005 par value; 250,000,000 shares | ||||||
Additional paid-in-capital | 232,426 | 227,058 | ||||
Treasury stock | (116) | (116) | ||||
Accumulated deficit | (244,658) | (236,943) | ||||
Total stockholders' deficit | $ | (12,332) | $ | (9,985) | ||
Total liabilities and stockholders' deficit | $ | 840 | $ | 1,022 | ||
The accompanying notes are an integral part of the consolidated financial statements.
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES | ||||||||||||
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) | ||||||||||||
U.S. dollars in thousands | ||||||||||||
(Except share and per share amounts) | ||||||||||||
Nine months ended | Three months ended | |||||||||||
September 30, | September 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Unaudited | Unaudited | |||||||||||
Operating expenses: | ||||||||||||
Research and development, net | $ | 2,248 | $ | 3,323 | $ | 523 | $ | 899 | ||||
General and administrative | 5,026 | 4,386 | 1,092 | 1,148 | ||||||||
Operating loss | (7,274) | (7,709) | (1,615) | (2,047) | ||||||||
Financial income (expense), net | (441) | (343) | (118) | (59) | ||||||||
Gain (loss) on change in | - | 179 | - | - | ||||||||
Net loss | $ | (7,715) | $ | (7,873) | $ | (1,733) | $ | (2,106) | ||||
Basic and diluted net loss | $ | (0.68) | $ | (0.91) | $ | (0.14) | $ | (0.19) | ||||
Weighted average number | 11,354,405 | 8,673,908 | 11,983,241 | 11,008,047 | ||||||||
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect," a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), the Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will", "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at
http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. BrainStorm does not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although BrainStorm believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com
Media:
Uri Yablonka, Chief Business Officer
Phone: +1 917-284-2911
uri@brainstorm-cell.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-third-quarter-2026-financial-results-and-provides-corporate-update-302940842.html
This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.
AlphAI analysis
Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.
The 30-second read
Why it matters
For traders, the key decision inputs are (1) whether the company is progressing toward Phase 3b initiation under the SPA and (2) whether the quarterly cash burn and balance-sheet deficit increase near-term dilution or financing risk.
Market read
This is a company-specific quarterly print plus operational/regulatory update that can move small-cap biotech positioning, but it lacks a definitive trial start date or financing disclosure.
What to watch
Cash is only about $0.35M at Sept. 30, 2026 and liabilities are large versus equity deficit, so traders may focus more on financing risk than on regulatory progress.
Background
BrainStorm Cell Therapeutics is advancing NurOwn (MSC-NTF cells) for ALS under an FDA-agreed Special Protocol Assessment, and this release combines Q3 2026 financials with Phase 3b ENDURANCE readiness and leadership/regulatory updates.
Ticker impact
BrainStorm reports Q3 2026 cash and net loss, and updates Phase 3b ENDURANCE readiness for NurOwn under an FDA-agreed SPA.
Likely modest support from the Phase 3b readiness and leadership/regulatory focus, offset by concerns over low cash and ongoing losses.
The article is a company-specific quarterly results plus operational update. It provides concrete financial datapoints (cash, net loss) and specific program/regulatory actions (SPA, Phase 3b preparations, executive chairman appointment), but it does not disclose a new trial start date, funding raise, or trial outcome that would be a major re-rating catalyst.
Market effects
Adds incremental sentiment to the small-cap adult stem cell/ALS biotech space via continued FDA-aligned Phase 3b planning.
Limited direct impact beyond OTC microcap biotech sentiment.
Low, as the story is company-specific and not tied to a global regulatory or market-wide event.
Counterpoint
The Phase 3b readiness language may not translate into imminent enrollment or trial initiation, while liquidity remains very tight.
Key entities
- companyBrainStorm Cell Therapeutics Inc.
OTCQB-listed developer of autologous adult stem cell therapeutics for neurodegenerative diseases, reporting Q3 2026 results and Phase 3b ENDURANCE readiness for NurOwn.
- programNurOwn
MSC-NTF cell therapy platform for ALS, with Phase 3b ENDURANCE preparations under an FDA-agreed SPA.
- regulatorFDA
Referenced for the Special Protocol Assessment and for launching a Rare Disease Framework Initiative in October 2026.
- executiveProfessor Peter J. Pitts
Appointed Executive Chairman and Chief Strategic Regulatory and Policy Officer to lead regulatory, operational, partnership, and capital-markets initiatives.